- Category: Experimental HCV Drugs
- Published on Wednesday, 11 June 2014 00:00
- Written by Merck, Achillion
Merck this week announced that it will purchase Idenix, a specialty biopharmaceutical company developing several hepatitis C virus (HCV) drug candidates. In related news, Achillion announced that the U.S. Food and Drug Administration (FDA) has lifted a clinical hold on one of its drugs and a clinical trial of another is now underway.